Delivering quality affordable medicines while enhancing stakeholder value responsibly
Committed management team aligned with shareholder interest
Decentralised in-country structures enable local teams to operate with entrepreneurial flair, creating value by applying local experience
12,9% Shareholding by executive management
A purpose-driven strategy with the promotion of access to medicine at its core
Manufactured 225 million doses of COVID vaccines and signed a 10-year agreement with the Serum Institute of India Pvt Ltd (”Serum Institute”) promoting access to vaccines in Africa
Supplied 180 medicines appearing on the Essential Medicines List to 60 low- to middle‑income countries
Consistent inclusion in the FTSE/JSE Responsible Investment Index since 2016 and member of the FTSE4GoodIndex
Commercial Pharmaceuticals: branded post-patent global and domestic products
Commercial Pharmaceuticals portfolio supported by a global footprint weighted to emerging markets with emerging market fundamentals
* Commercial Pharmaceuticals revenues in 2022 and 2021
excludes revenues from products divested in SA in 2022.
Headroom to invest in the Commercial Pharmaceuticals portfolio, inherent to portfolio growth strategy
Delivering quality affordable medicines while enhancing stakeholder value responsibly
Manufacturing: Capacities for own and third-party use
Widely accredited and compliant API and FDF manufacturing capabilities with increasing focus on complex sterile capacities
Increasing returns as sterile manufacturing capacities come online
Strategically relevant manufacturing capacities to deliver accelerated growth
Capabilities/dosage forms:
- Ampoules
- Blow-fill seal
- Eye drops
- Lyophilized products
- Prefilled syringes
- Vials
Therapies:
- Ampoules
- Blow-fill seal
- Eye drops
- Lyophilized products
- Prefilled syringes
- Vials
